CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: January 8, 2020
Result type: Reports
Project Number: SR0624-000
Product Line: Common Drug Review

Generic Name: tildrakizumab

Brand Name: Ilumya

Manufacturer: Sun Pharma Canada

Indications: Psoriasis, moderate to severe plaque

Manufacturer Requested Reimbursement Criteria1: Tildrakizumab is expected to be indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Submission Type: New

Project Status: Suspended

Companion Diagnostics: Yes

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input postedJune 11, 2019
Patient group input closedJuly 31, 2019

- Patient input submission received from the Canadian Association of Psoriasis Patients, the Canadian Organization for Rare Disorders, the Canadian Psoriasis Network and the Canadian Skin Patient Alliance

Patient input summary sent for review to patient input groupsSeptember 05, 2019
Patient group comments on input summary closedSeptember 12, 2019

- Patient input summary feedback received

Submission receivedJuly 15, 2019
Submission acceptedAugust 26, 2019

- Submission was not accepted for review on 29 Jul 2019

Review initiatedAugust 27, 2019
Draft CADTH review report(s) sent to sponsorNovember 11, 2019
Comments from sponsor on draft CADTH review report(s) receivedNovember 20, 2019

Sponsor waived the opportunity to provide comments

- Submission temporarily suspended